Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.61

-0.7%

4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (1371)	7/30/2002 1:55:15 AM
From: Icebrg	Read Replies (2) of 1475

TexasDude As I read this, it means that they will not wait for Eligix US approval before they push forward with the Allumune trials. They will use the next best technology instead. Later upon approval of the concerned Eligix' device, they can switch. From the PR issued upon acquiring Eligix. There is a significant strategic fit between the two companies that will help to position BioTransplant as an industry leader in immune modulation therapy for transplantation in cancer and other serious diseases. BioTransplant's AlloMune(TM) System will benefit from Eligix' device, enabling BioTransplant to offer, along with the MEDI-507 antibody, a comprehensive approach to increase the safety and efficacy of transplantation for cancer and other diseases. Ice

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next